Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRMD NASDAQ:IMTX NASDAQ:NLTX NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRMDCorMedix$11.95-0.9%$12.59$3.61▼$17.43$817.63M1.711.84 million shs882,339 shsIMTXImmatics$6.34-4.7%$5.97$3.30▼$13.09$808.31M0.93387,053 shs352,349 shsNLTXNeoleukin Therapeutics$21.45-1.2%$20.22$2.03▼$14.36$201.59M1.1150,104 shs139,566 shsPROKProKidney$2.88-9.4%$1.92$0.46▼$7.13$930.78M1.7621.42 million shs3.17 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRMDCorMedix-0.91%+3.55%+4.64%-0.79%+195.43%IMTXImmatics-4.66%-5.09%+14.65%+45.58%-43.44%NLTXNeoleukin Therapeutics-1.24%-1.06%+6.77%+54.76%-41.71%PROKProKidney-9.43%+7.06%+374.86%+308.51%+56.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRMDCorMedix2.5591 of 5 stars4.41.00.00.02.80.00.6IMTXImmatics2.1596 of 5 stars3.64.00.00.00.61.70.0NLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APROKProKidney3.1814 of 5 stars3.24.00.00.02.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRMDCorMedix 2.88Moderate Buy$17.1443.45% UpsideIMTXImmatics 3.20Buy$14.67131.34% UpsideNLTXNeoleukin Therapeutics 0.00N/AN/AN/APROKProKidney 2.40Hold$6.25117.01% UpsideCurrent Analyst Ratings BreakdownLatest NLTX, IMTX, CRMD, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025PROKProKidneyUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$4.00 ➝ $8.007/14/2025PROKProKidneyGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $7.007/9/2025PROKProKidneyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $9.006/30/2025CRMDCorMedixD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/30/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold6/30/2025CRMDCorMedixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.006/30/2025PROKProKidneyBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeNeutral ➝ Underperform$3.00 ➝ $1.006/24/2025CRMDCorMedixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.006/23/2025CRMDCorMedixD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.006/20/2025CRMDCorMedixRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.005/28/2025IMTXImmaticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 8/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRMDCorMedix$43.47M18.64N/AN/A$1.40 per share8.54IMTXImmatics$168.65M4.57$0.23 per share27.22$5.12 per share1.24NLTXNeoleukin TherapeuticsN/AN/AN/AN/A$11.08 per shareN/APROKProKidney$80K10,537.20N/AN/A($3.41) per share-0.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRMDCorMedix-$17.93M$0.2254.3212.71N/A20.81%22.57%17.02%8/13/2025 (Estimated)IMTXImmatics$16.47M-$0.17N/AN/AN/A-14.73%-4.52%-3.34%8/12/2025 (Estimated)NLTXNeoleukin Therapeutics-$57.56M-$3.11N/A∞N/AN/A-37.22%-30.91%N/APROKProKidney-$61.19M-$0.60N/AN/AN/AN/AN/A-15.03%8/8/2025 (Estimated)Latest NLTX, IMTX, CRMD, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025CRMDCorMedix$0.17N/AN/AN/A$29.88 millionN/A8/12/2025Q1 2025IMTXImmatics-$0.38N/AN/AN/A$13.05 millionN/A8/8/2025Q2 2025PROKProKidney-$0.14N/AN/AN/AN/AN/A5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/12/2025Q1 2025PROKProKidney-$0.16-$0.13+$0.03-$0.13N/A$0.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRMDCorMedixN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ANLTXNeoleukin TherapeuticsN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRMDCorMedixN/A4.213.99IMTXImmaticsN/A10.2810.28NLTXNeoleukin TherapeuticsN/A15.3315.33PROKProKidneyN/A10.9610.96Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRMDCorMedix34.18%IMTXImmatics64.41%NLTXNeoleukin Therapeutics52.37%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipCRMDCorMedix5.30%IMTXImmatics3.30%NLTXNeoleukin Therapeutics1.58%PROKProKidney41.49%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRMDCorMedix3067.82 million64.23 millionOptionableIMTXImmatics260121.55 million117.54 millionOptionableNLTXNeoleukin Therapeutics909.40 million9.25 millionNo DataPROKProKidney3292.70 million171.26 millionOptionableNLTX, IMTX, CRMD, and PROK HeadlinesRecent News About These CompaniesProKidney (NASDAQ:PROK) Stock Price Up 10% - Should You Buy?August 1, 2025 | marketbeat.comProKidney (PROK) to Release Quarterly Earnings on FridayAugust 1, 2025 | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Down 7.8% - What's Next?July 29, 2025 | marketbeat.comProKidney Stock Skyrockets But Greensboro Is Still Empty HandedJuly 25, 2025 | rhinotimes.comRProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy AdvancementJuly 22, 2025 | msn.comMeet the Biotech Stock That Rocketed 775% HigherJuly 22, 2025 | fool.comProKidney (NASDAQ:PROK) Shares Gap Up - Here's WhyJuly 21, 2025 | marketbeat.comJP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)July 20, 2025 | insidermonkey.comProKidney (NASDAQ:PROK) Shares Down 4.1% - Time to Sell?July 18, 2025 | marketbeat.comPROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?July 17, 2025 | zacks.comBest Momentum Stocks to Buy for July 17thJuly 17, 2025 | zacks.comNew Strong Buy Stocks for July 17thJuly 17, 2025 | zacks.comProKidney gains pivotal therapy advancement step with FDAJuly 17, 2025 | journalnow.comJProKidney Corp. (PROK) is a Great Momentum Stock: Should You Buy?July 16, 2025 | zacks.comPromising clinical trial results give ProKidney share price major boostJuly 15, 2025 | journalnow.comJProKidney stock soars after FDA confirms accelerated approval pathwayJuly 15, 2025 | in.investing.comProKidney Shares Dip Following FDA Agreement on Rilparencel Approval StrategyJuly 15, 2025 | msn.comProKidney Shares Surge in Early Trading On FDA Support for Kidney Drug TrialJuly 15, 2025 | marketwatch.comProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for RilparencelJuly 15, 2025 | finance.yahoo.comProKidney (NASDAQ:PROK) Trading 7.5% Higher After Analyst UpgradeJuly 15, 2025 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Receives Average Recommendation of "Hold" from BrokeragesJuly 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNLTX, IMTX, CRMD, and PROK Company DescriptionsCorMedix NASDAQ:CRMD$11.95 -0.11 (-0.91%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$19.00 +7.05 (+59.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.Immatics NASDAQ:IMTX$6.34 -0.31 (-4.66%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$6.43 +0.09 (+1.42%) As of 04:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Neoleukin Therapeutics NASDAQ:NLTX$21.45 -0.27 (-1.24%) As of 08/5/2025Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.ProKidney NASDAQ:PROK$2.88 -0.30 (-9.43%) Closing price 08/6/2025 04:00 PM EasternExtended Trading$2.98 +0.10 (+3.30%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Joby Deal Gives Blade New Direction, But Stock Lacks Lift How DigitalOcean's Focus Is Fueling Explosive Growth Disney’s Iger-Led Turnaround Gains Traction Can Celsius Stock Keep Its Momentum Going Any Longer? AMD’s Results Sparked a Sell-Off—But That’s Your Buy Signal Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 Lifeline Does Broadcom Have a VMware Problem? Goldman Eyes Upside in NTNX RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
